Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
have become a major concern in the containment of current pandemic. The variants …

Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …

The emergence of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants of concern threatens the efficacy of currently approved vaccines and authorized …

B cells specific for the SARS-CoV-2 S envelope glycoprotein spike were isolated from a
COVID-19-infected subject using a stabilized spike-derived ectodomain (S2P) twenty-one …

The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …

Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

Antibodies are a principal determinant of immunity for most RNA viruses and have promise
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …

Potent neutralizing SARS-CoV-2 antibodies often target the spike protein receptor-binding
site (RBS), but the variability of RBS epitopes hampers broad neutralization of multiple …